On Jan 07, major Wall Street analysts update their ratings for $Denali Therapeutics (DNLI.US)$, with price targets ranging from $24 to $87.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $28 to $24.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $45.
Baird analyst Joel Beatty initiates coverage with a buy rating, and sets the target price at $31.
Stifel analyst Paul Matteis maintains with a buy rating.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $35 to $32.
Furthermore, according to the comprehensive report, the opinions of $Denali Therapeutics (DNLI.US)$'s main analysts recently are as follows:
The recent results from the Phase 2/3 HEALEY trial, testing an agonist of eIF2B for amyotrophic lateral sclerosis, highlighted the failure of DNL343. Despite the strong pre-clinical evidence suggesting reduced aggregation of major ALS pathology drivers such as TDP-43, the outcome was disappointing. Additionally, this was one of the last legacy programs at Denali, with a stated company focus shifting towards TV-oriented development pipeline in the future.
Denali Therapeutics is positioned to transform into a commercial entity by late 2025 or early 2026, largely thanks to the anticipated expedited FDA approval of its forefront treatment, tividenofusp alfa, designed for Hunter syndrome. This enzyme replacement therapy's ability to penetrate the brain suggests it could swiftly capture a notable portion of the market currently served by Elaprase, which generates $700M in annual sales. Additionally, Denali's early-stage 'Peak 2' projects aimed at addressing Alzheimer's and Parkinson's disease represent promising ventures for future growth.
Here are the latest investment ratings and price targets for $Denali Therapeutics (DNLI.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间1月7日，多家华尔街大行更新了$Denali Therapeutics (DNLI.US)$的评级，目标价介于24美元至87美元。
摩根大通分析师Jessica Fye维持买入评级，并将目标价从28美元下调至24美元。
富瑞集团分析师Michael Yee维持买入评级，维持目标价45美元。
贝雅分析师Joel Beatty首予买入评级，目标价31美元。
斯迪富分析师Paul Matteis维持买入评级。
BTIG分析师Thomas Shrader维持买入评级，并将目标价从35美元下调至32美元。
此外，综合报道，$Denali Therapeutics (DNLI.US)$近期主要分析师观点如下：
最近的HEALEY二期/三期试验结果测试了一种针对肌萎缩侧索硬化症的eIF20亿激动剂，突出了DNL343的失败。尽管有强有力的前临床证据表明减少了重大ALS病理驱动因子如TDP-43的聚集，但结果令人失望。此外，这是Denali的最后几个遗留项目之一，该公司的重点已转向未来以电视为导向的发展管道。
Denali Therapeutics预计将在2025年底或2026年初转型为一个商业实体，这主要得益于其前沿治疗方案tividenofusp alfa的FDA加速批准，该方案旨在治疗亨特综合症。这种酶替代疗法能够穿透大脑，表明它可以迅速捕获目前由Elaprase提供的市场的显著份额，Elaprase的年销售额为70000万美元。此外，Denali的早期阶段“Peak 2”项目旨在解决阿尔茨海默病和帕金森病，为未来增长代表了有前景的投资。
以下为今日6位分析师对$Denali Therapeutics (DNLI.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
